Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 1996;27:1193-1199

This Article
Right arrow Full Text
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mune, T.
Right arrow Articles by White, P. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mune, T.
Right arrow Articles by White, P. C.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*High Blood Pressure
Hazardous Substances DB
*HYDROCORTISONE

(Hypertension. 1996;27:1193-1199.)
© 1996 American Heart Association, Inc.


Articles

Apparent Mineralocorticoid Excess

Genotype Is Correlated With Biochemical Phenotype

Tomoatsu Mune; Perrin C. White

From the Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas.

Abstract The syndrome of apparent mineralocorticoid excess is a form of hypertension inherited in an autosomal recessive manner. This disorder results from mutations in the HSD11K (HSD11B2) gene, which encodes the kidney isozyme of 11ß-hydroxysteroid dehydrogenase. This enzyme converts active glucocorticoids such as cortisol and corticosterone to their inactive metabolites cortisone and 11-dehydrocorticosterone. An elevated ratio of cortisol to cortisone metabolites in the urine (tetrahydrocortisol plus allotetrahydrocortisol to tetrahydrocortisone [(THF+aTHF)/THE]) is considered pathognomic for this disorder. To determine whether the biochemical phenotype of this disorder is correlated with genotype, we expressed enzymes carrying each of the six known missense mutations in cultured cells. Only one mutant, R337C, had detectable activity in cell lysates, but five of six mutants were partially active in whole cells. Apparent kinetic constants for cortisol and corticosterone were determined in whole cells, and the apparent first-order rate constant, Vmax/Km, was used as a measure of enzymatic activity. The urinary (THF+aTHF)/THE ratio in patients carrying each mutation was strongly correlated with in vitro enzymatic activity of the corresponding mutant (r=.839, P=.001 with cortisol as the substrate). We conclude that the biochemical phenotype of the syndrome of apparent mineralocorticoid excess is largely determined by genotype.


Key Words: steroids • mineralocorticoids • kidney • corticosterone • hypertension, genetic • hypertension, endocrine • molecular biology




This article has been cited by other articles:


Home page
J. Am. Soc. Nephrol.Home page
A. G. Atanasov, I. D. Ignatova, L. G. Nashev, B. Dick, P. Ferrari, F. J. Frey, and A. Odermatt
Impaired Protein Stability of 11beta-Hydroxysteroid Dehydrogenase Type 2: A Novel Mechanism of Apparent Mineralocorticoid Excess
J. Am. Soc. Nephrol., April 1, 2007; 18(4): 1262 - 1270.
[Abstract] [Full Text] [PDF]


Home page
J EndocrinolHome page
N. Draper and P. M Stewart
11{beta}-Hydroxysteroid dehydrogenase and the pre-receptor regulation of corticosteroid hormone action
J. Endocrinol., August 1, 2005; 186(2): 251 - 271.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
T. Mune, H. Murase, N. Yamakita, T. Fukuda, M. Murayama, A. Miura, T. Suwa, J. Hanafusa, H. Daido, H. Morita, et al.
Eutopic Overexpression of Vasopressin V1a Receptor in Adrenocorticotropin-Independent Macronodular Adrenal Hyperplasia
J. Clin. Endocrinol. Metab., December 1, 2002; 87(12): 5706 - 5713.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
S. Kataoka, A. Kudo, H. Hirano, H. Kawakami, T. Kawano, E. Higashihara, H. Tanaka, F. Delarue, J.-D. Sraer, T. Mune, et al.
11{beta}-Hydroxysteroid Dehydrogenase Type 2 Is Expressed in the Human Kidney Glomerulus
J. Clin. Endocrinol. Metab., February 1, 2002; 87(2): 877 - 882.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
A. Odermatt, B. Dick, P. Arnold, T. Zaehner, V. Plueschke, M. N. Deregibus, H. Repetto, B. M. Frey, F. J. Frey, and P. Ferrari
A Mutation in the Cofactor-Binding Domain of 11{beta}-Hydroxysteroid Dehydrogenase Type 2 Associated with Mineralocorticoid Hypertension
J. Clin. Endocrinol. Metab., March 1, 2001; 86(3): 1247 - 1252.
[Abstract] [Full Text]


Home page
Am. J. Physiol. Renal Physiol.Home page
N. Farman and M.-E. Rafestin-Oblin
Multiple aspects of mineralocorticoid selectivity
Am J Physiol Renal Physiol, February 1, 2001; 280(2): F181 - F192.
[Abstract] [Full Text] [PDF]


Home page
IOVSHome page
J. Stokes, J. Noble, L. Brett, C. Phillips, J. R. Seckl, C. O’Brien, and R. Andrew
Distribution of Glucocorticoid and Mineralocorticoid Receptors and 11{beta}-Hydroxysteroid Dehydrogenases in Human and Rat Ocular Tissues
Invest. Ophthalmol. Vis. Sci., June 1, 2000; 41(7): 1629 - 1638.
[Abstract] [Full Text]


Home page
J. Biol. Chem.Home page
A. Odermatt, P. Arnold, A. Stauffer, B. M. Frey, and F. J. Frey
The N-terminal Anchor Sequences of 11beta -Hydroxysteroid Dehydrogenases Determine Their Orientation in the Endoplasmic Reticulum Membrane
J. Biol. Chem., October 1, 1999; 274(40): 28762 - 28770.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
B. S. Nunez, F. M. Rogerson, T. Mune, Y. Igarashi, Y. Nakagawa, G. Phillipov, A. Moudgil, L. B. Travis, M. Palermo, C. Shackleton, et al.
Mutants of 11{beta}-Hydroxysteroid Dehydrogenase (11-HSD2) With Partial Activity : Improved Correlations Between Genotype and Biochemical Phenotype in Apparent Mineralocorticoid Excess
Hypertension, October 1, 1999; 34(4): 638 - 642.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
G. Morineau, J.-M. Marc, A. Boudi, H. Galons, M. Gourmelen, P. Corvol, L. Pascoe, and J. Fiet
Genetic, Biochemical, and Clinical Studies of Patients With A328V or R213C Mutations in 11{beta}HSD2 Causing Apparent Mineralocorticoid Excess
Hypertension, September 1, 1999; 34(3): 435 - 441.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
M. Palermo, M. Cossu, and C. H.L. Shackleton
Cure of Apparent Mineralocorticoid Excess by Kidney Transplantation
N. Engl. J. Med., December 10, 1998; 339(24): 1787 - 1788.
[Full Text]


Home page
Cardiovasc ResHome page
S. H.M. van Uum, A. R.M.M. Hermus, P. Smits, T. Thien, and J. W.M. Lenders
The role of 11{beta}-hydroxysteroid dehydrogenase in the pathogenesis of hypertension
Cardiovasc Res, April 1, 1998; 38(1): 16 - 24.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
R. E. Smith, L. A. Salamonsen, P. A. Komesaroff, K. X. Z. Li, K. M. Myles, M. Lawrence, and Z. Krozowski
11{beta}-Hydroxysteroid Dehydrogenase Type II in the Human Endometrium: Localization and Activity during the Menstrual Cycle
J. Clin. Endocrinol. Metab., December 1, 1997; 82(12): 4252 - 4257.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
P. C. White, T. Mune, and A. K. Agarwal
11{beta}-Hydroxysteroid Dehydrogenase and the Syndrome of Apparent Mineralocorticoid Excess
Endocr. Rev., February 1, 1997; 18(1): 135 - 156.
[Abstract] [Full Text]


Home page
HypertensionHome page
P. C. White
Inherited Forms of Mineralocorticoid Hypertension
Hypertension, December 1, 1996; 28(6): 927 - 936.
[Abstract] [Full Text]